NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Company N.V. (NAMS) SEC Filings & 10-K Annual Reports
SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.
SEC EDGAR · data.sec.gov · CIK 0001936258 · NAMS · NASDAQ · as of Jun 8, 2026
Filing snapshot
Source: SEC EDGAR (data.sec.gov) · CIK 0001936258 · Updated hourly · Not investment advice
Latest Annual Report
Latest Key Filings
Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.
SEC Filing History
About SEC Filings & 10-K Annual Reports
NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS) has submitted 392 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2021. As a Healthcare sector company with CIK 0001936258, all filings are publicly accessible via the EDGAR database at no cost.
The annual 10-K report is NewAmsterdam Pharma Company N.V.'s most comprehensive regulatory disclosure. The most recent NewAmsterdam Pharma Company N.V. 10-K was filed on 2026-02-18 for fiscal year ending 2026. Historical NAMS 10-K annual reports are available from 2022 through 2026.
Investors researching NewAmsterdam Pharma Company N.V. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.
Frequently Asked Questions
NAMS SEC Filings · 8 questionsNewAmsterdam Pharma Company N.V. (NAMS) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 392 filings and access original documents at no cost. NewAmsterdam Pharma Company N.V.'s CIK is 0001936258.